Eplontersen: A Breakthrough in Treating Hereditary Transthyretin-Mediated Amyloidosis

Eplontersen: A Breakthrough in Treating Hereditary Transthyretin-Mediated Amyloidosis The recent approval of eplontersen, marketed as Wainzua, marks a significant advancement in the treatment of hereditary transthyretin-mediated amyloidosis (ATTR), a rare and progressive condition that has long challenged the medical community. This disease is characterized by the accumulation of misfolded transthyretin (TTR) protein in various tissues, […]